Literature DB >> 20733114

Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Andrew M Tonkin1, Lei Chen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20733114     DOI: 10.1161/CIRCULATIONAHA.110.960112

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  6 in total

Review 1.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

Review 2.  Fenofibrate: a review of its use in dyslipidaemia.

Authors:  Kate McKeage; Gillian M Keating
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

Review 3.  Therapeutic approaches to diabetic nephropathy--beyond the RAS.

Authors:  Beatriz Fernandez-Fernandez; Alberto Ortiz; Carmen Gomez-Guerrero; Jesus Egido
Journal:  Nat Rev Nephrol       Date:  2014-05-06       Impact factor: 28.314

Review 4.  Origin and therapy for hypertriglyceridaemia in type 2 diabetes.

Authors:  Jing Pang; Dick C Chan; Gerald F Watts
Journal:  World J Diabetes       Date:  2014-04-15

Review 5.  Critical appraisal of international guidelines for the management of diabetic neuropathy: is there global agreement in the internet era?

Authors:  Mingfang Sun; Min Zhang; Jing Shen; Juping Yan; Bo Zhou
Journal:  Int J Endocrinol       Date:  2015-04-27       Impact factor: 3.257

Review 6.  The metabolic vascular syndrome - guide to an individualized treatment.

Authors:  Markolf Hanefeld; Frank Pistrosch; Stefan R Bornstein; Andreas L Birkenfeld
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.